We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer.
- Authors
Bian, Qiang; Li, Bei; Zhang, Luting; Sun, Yinuo; Zhao, Zhankui; Ding, Yi; Yu, Honglian
- Abstract
Prostate cancer is the second incidence of malignant tumors in men worldwide. Its incidence and mortality are increasing year by year. Enhanced expression of Cav1 in prostate cancer has been linked to both proliferation and metastasis of cancer cells, influencing disease progression. Dysregulation of the Cav1 gene shows a notable association with prostate cancer. Nevertheless, there is no systematic review to report about molecular signal mechanism of Cav1 and drug treatment in prostate cancer. This article reviews the structure, physiological and pathological functions of Cav1, the pathogenic signaling pathways involved in prostate cancer, and the current drug treatment of prostate cancer. Cav1 mainly affects the occurrence of prostate cancer through AKT/mTOR, H-RAS/PLCε, CD147/MMPs and other pathways, as well as substance metabolism including lipid metabolism and aerobic glycolysis. Baicalein, simvastatin, triptolide and other drugs can effectively inhibit the growth of prostate cancer. As a biomarker of prostate cancer, Cav1 may provide a potential therapeutic target for the treatment of prostate cancer.
- Subjects
PROSTATE cancer; PROSTATE cancer treatment; CARCINOGENESIS; METASTASIS; CANCER invasiveness; CANCER cells; SIMVASTATIN; TRIPTOLIDE
- Publication
Discover Oncology, 2023, Vol 14, Issue 1, p1
- ISSN
2730-6011
- Publication type
Article
- DOI
10.1007/s12672-023-00813-0